About 341 results for "sandoz inc"

Sandoz Inc. - Pharmaceuticals & Healthcare - Deals and Allianc...

Sandoz Inc. (Sandoz), a subsidiary of Sandoz International GmbH, is a manufacturer of pharmaceutical products. It is indirectly owned by Novartis AG. The company develops, produces and markets generic pharmaceutical products, follow-on ... TransWorldNews, 4 days ago

Amgen (AMGN), Hospira, Inc. (HSP) and Sandoz, Inc. Named Among Top Pharmaceutical Companies With Greatest Biosimilar Drug Potential in United States - BioSpace, 1 week ago

Amgen, Hospira, Inc. and Sandoz, Inc. Named Among Top Pharmaceutical Companies With Greatest Biosimilar Drug Potential in United States - BioSpace, 1 week ago

Patent Watch: Allergan, Inc. v. Sandoz Inc.

There is no requirement in patent law that the person of ordinary skill be motivated to develop the claimed invention based on a rationale that forms the basis for FDA approval. On May 1, 2013, in Allergan, Inc. v. Sandoz Inc., the U.S. Court of ...

JD Supra, 2 weeks ago Federal Circuit Upholds One Claim Covering Combigan JD Supra, 2 weeks ago Allergan, Inc. v. Sandoz Inc. (Fed. Cir. 2013) JD Supra, 2 weeks ago Federal Circuit Finds Yaz Patent Obvious JD Supra, 3 weeks ago

BusinessWeek

Reports: Actavis Spurns $15 Bln Bid From Mylan To Pursue Warner Chilcott Deal

Generic drug maker Actavis, Inc., which acquired Watson Pharmaceuticals, Inc., is said to have spurned a $15 billion cash and stock acquisition offer from rival Mylan, Inc. (MYL: Quote), according to media reports on Tuesday. The company instead ...

RTTNews.com, 1 week ago Actavis Seen Deserving Second-Best Valuation in Sale: Real M BusinessWeek, 3 weeks ago Actavis Seen Selling for Higher Valuation: Real M Bloomberg, 3 weeks ago

Celltrion Drops Late-Stage Trial of Roche Rituxan Drug Copy

Celltrion Inc. (068270) dropped a late-stage trial of a biosimilar version of Roche Holding AG (ROG)'s best-selling Rituxan drug, potentially benefiting competitors such as Boehringer Ingelheim GmbH and Novartis (NOVN) AG. Celltrion had planned to ...

BusinessWeek, 1 month ago Celltrion Postpones Late-Stage Trial of Roche Rituxan Copy Washington Post, 1 month ago

Sharenet

Actavis to Sell Generic Yaz After Victorious Court Ruling; Irvine Personal Injury Lawyer Jeff Nadrich Responds

Drug maker Actavis Inc. has announced that the company will resume sales of a generic version of the popular oral contraceptive Yaz, after an appeals court ruled that Bayer's patent for the drug was invalid. As Reuters reports, this U.S. Court of ...

Pharmacy Choice, 1 week ago UPDATE 2-Actavis to sell generic Yaz birth control after ruling Reuters, 1 month ago Actavis to sell generic Yaz birth control after ruling Yahoo!, 1 month ago UPDATE 1-US court finds Bayer contraceptive patent claim invalid Reuters, 1 month ago

More from: MedCity News, CNBC...and 8 other sources

[x]

Rajiv Malik appointed to the Board of Directors of Mylan Inc.

Rajiv Malik has been recently appointed to board of the Mylan Inc., one of the largest pharmaceutical companies in the world. He is one of the most successful pharmaceutical professionals of Indian origin and is part of growing list of the Indians, ...

PharmaBiz, 1 month ago

News-Medical.Net

Patient Compliance: an Interview With Innovus Pharma CEO Damaj Outlines Worldwide Growth Plans for the Company

(GLOBE NEWSWIRE) -- Innovus Pharmaceuticals, Inc., ("Innovus Pharma") www.innovuspharma.com (OTCBB:INNV), today announced that Dr. Bassam Damaj, Chief Executive Officer, was recently interviewed by News-Medical.Net medical information service. The ...

Asian Hospital & Healthcare Management, 1 day ago INNOVUS PHARMACEUTICALS INC : Patient Compliance: an Interview With Innovus Pharma CEO Damaj Outlines Worldwide Growth Plans for the Company 4 Traders, 1 day ago INNOVUS PHARMACEUTICALS INC: Innovus Pharma Announces the Appointment of Bassam Damaj as President & Chief Executive Officer 4 Traders, 1 week ago Innovus Pharma CEO to Present at the BIO Business Forum in Chicago Scottrade, 1 month ago

More from: Pharmacy Choice, Individual.com...and 18 other sources

[x]

Court Report -- May 19, 2013

About Court Report: Each week we will report briefly on recently filed biotech and pharma cases. • Plaintiff: AbbVie Inc. • Defendants: Hetero USA Inc.; Hetero Labs Ltd. Infringement of U.S. Patent Nos. 7,148,359 ("Polymorph of a ...

JD Supra, 2 days ago Momenta Pharmaceuticals Reports First Quarter 2013 Financial Results Pharmacy Choice, 3 weeks ago 1st Quarter Results TrustNet, 4 weeks ago

More from: , Equities.com...and 5 other sources, Equities.com...and 5 other sources

[x]

Atrium Innovations proposes San Juan as director

A new director nominee will be included in the management proxy circular of Atrium Innovations Inc. for election at the next annual general meeting of shareholders to be held on May 14, 2013. The new proposed nominee is Javier San Juan, president ...

Stockwatch, 1 month ago Atrium Innovations Announces a New Director Nominee for Election at the 2013 Annual General Meeting TickerTech.com, 1 month ago

More from: Gnom.es, Individual.com...and 8 other sources

[x]

MFLX, LOJN, MNTA, CUK, HOME Are Seasonally Ripe To Go Down In the Next Five Weeks

BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of Multi-Fineline Electronix Inc (NASDAQ:MFLX), LoJack Corp (NASDAQ:LOJN), Momenta Pharmaceuticals Inc (NASDAQ:MNTA), Carnival PLC (NYSE:CUK), Home Federal Bancorp Inc (NASDAQ:HOME) ...

TradingCharts.com, 1 month ago BUYINS.NET: MFLX, LOJN, MNTA, CUK, HOME Are Seasonally Ripe To Go Down In the Next Five Weeks TMC Net, 1 month ago

Prev | Next